“Lessons on pathogenesis of Spondyloarthritis from SKG mice” - Ranjeny Thomas
Professor Thomas´ research is focused on the study of the biology and clinical use of human dendritic cells in autoimmune disease. It has explored basic mechanisms of immunity and dendritic cell function in autoimmune disease. Professor Thomas is graduate of the University of Western Australia. She received her MBBS in 1984, and then trained in Perth as a rheumatologist. She commenced a research fellowship with Peter Lipsky at Southwestern Medical Center, University of Texas in 1990, where she first identified and characterised human circulating dendritic cell precursors. She is now Professor of Rheumatology at University of Queensland Diamantina Institute, Translational Research Institute, consultant Rheumatologist at Princess Alexandra Hospital and fellow of the Australian Academy of Health and Medical Sciences. Her research is focused on the study of autoimmune disease and restoration of tolerance. Through this work, she developed and tested the first rheumatoid arthritis vaccine. She has also contributed major insights into the pathogenesis of spondyloarthropathy and autoimmune diabetes, leading to the development of disease biomarkers and innovative immunotherapies. Ranjeny is a director of the spin-off company, Dendright, which is developing antigen-specific (personalised) immunotherapy and companion biomarkers to prevent and treat rheumatoid arthritis. She is funded by the Juvenile Diabetes Research Foundation to develop antigenspecific immunotherapy for children with type 1 diabetes.
- Zeng, Bijun, Middelberg, Anton P.J., Gemiarto, Adrian, MacDonald, Kelli, Baxter, Alan G, Talekar, Meghna, Moi, Davide, Tullet, KirsteenM, Caminschi, Irina, Lahoud, Mireille H, Mazzieri, Roberta, Dolcetti, Riccardo and Thomas, Ranjeny (2018) Selfadjuvanting nanoemulsion targeting dendritic cell receptor
Clec9A enables antigen-specific immunotherapy. The Journal of clinical investigation, 128 5: 1971-1984. Doi:10.1172/JCI96791